75 studies found for:    "Liposarcoma"
Show Display Options
Rank Status Study
21 Active, not recruiting Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Conditions: Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma of Bone;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Childhood Angiosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Hemangiopericytoma;   Childhood Malignant Mesenchymoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Metastatic Childhood Soft Tissue Sarcoma;   Mixed Childhood Rhabdomyosarcoma;   Pleomorphic Childhood Rhabdomyosarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: cixutumumab;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
22 Recruiting Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Childhood Epithelioid Hemangioendothelioma;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Hemangiopericytoma;   Childhood Malignant Mesenchymoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: gemcitabine hydrochloride;   Drug: pazopanib hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis
23 Active, not recruiting Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Synovial Sarcoma;   Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Mesenchymoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: doxorubicin hydrochloride;   Other: clinical observation;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Drug: ifosfamide
24 Completed An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Conditions: Ovarian Neoplasms;   Colorectal Neoplasms;   Melanoma;   Small Cell Lung Cancer;   Liposarcoma
Interventions: Radiation: Ionizing radiation (IR) therapy;   Radiation: Ionizing radiation (IR)
25 Active, not recruiting Rosiglitazone in Treating Patients With Liposarcoma
Condition: Sarcoma
Intervention: Drug: rosiglitazone maleate
26 Unknown  Troglitazone in Treating Patients With Liposarcoma
Condition: Sarcoma
Intervention: Drug: troglitazone
27 Unknown  Bevacizumab and Radiation Therapy for Sarcomas
Conditions: Soft Tissue Sarcoma;   Fibrous Histiocytoma;   Liposarcoma;   Leiomyosarcoma;   Fibrosarcoma;   Synovial Sarcoma
Interventions: Drug: Bevacizumab;   Procedure: Radiation Therapy
28 Completed Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Conditions: Leiomyosarcoma;   Liposarcoma;   Osteosarcoma;   Sarcoma, Soft Tissue;   Metastases
Intervention: Drug: ridaforolimus
29 Completed
Has Results
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Conditions: Liposarcoma;   Leiomyosarcoma;   Fibrosarcoma;   Malignant Fibrous Histiocytoma
Intervention: Drug: Sunitinib Malate (SU011248)
30 Recruiting Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
Conditions: Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Stage IIA Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: pazopanib hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Other: placebo;   Procedure: therapeutic conventional surgery;   Radiation: external beam radiation therapy;   Other: pharmacological study;   Other: laboratory biomarker analysis
31 Suspended Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Neurofibrosarcoma;   Chondrosarcoma;   Endometrial Stromal Sarcoma;   Mast Cell Sarcoma;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Ovarian Carcinosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: alisertib;   Other: laboratory biomarker analysis
32 Completed AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Conditions: Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Rhabdomyosarcoma;   Dermatofibrosarcoma Protuberans;   Endometrial Stromal Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Uterine Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma;   Uterine Carcinosarcoma;   Uterine Leiomyosarcoma
Intervention: Drug: saracatinib
33 Recruiting Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Dermatofibrosarcoma Protuberans;   Gastrointestinal Stromal Tumor;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Kaposi Sarcoma;   Recurrent Osteosarcoma;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma
Interventions: Drug: vismodegib;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
34 Active, not recruiting Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Gastrointestinal Stromal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Intervention: Drug: romidepsin
35 Active, not recruiting Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Conditions: Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Gliosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Osteosarcoma
Interventions: Biological: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
36 Completed A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery
Condition: Sarcoma
Intervention: Drug: RO5045337
37 Recruiting A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
Condition: Sarcoma
Intervention: Drug: Trabectedin
38 Completed Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Stromal Tumor;   Sarcoma
Interventions: Biological: sargramostim;   Biological: telomerase: 540-548 peptide vaccine
39 Completed Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
Conditions: Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions: Drug: celecoxib;   Procedure: adjuvant therapy;   Radiation: radiation therapy
40 Completed Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Condition: Life Threatening Diseases
Intervention: Drug: Imatinib mesylate

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years